GlaxoSmithKline, the maker of the shingles vaccine Shingrix that has been in short supply, told customers Jan. 10 that more shipments of the vaccine are on the way to U.S. pharmacies, according to WebMD.
While more doses are on the way, the company warned that demand may still outpace supply.
GlaxoSmithKline has ordering limits in place, so a single provider can't order and maintain a large stock.
This year the company said it plans to ramp up the frequency and volume of doses shipped.